Tracking Triple-negative Breast Cancer Evolution Through Therapy

Prior treatment

• Previous or current malignancies of other origin within the last 5 years, with the exception of in situ carcinoma of the cervix, and adequately treated basal cell or squamous cell carcinoma of the skin

Other illness

• Confirmed metastatic disease at initial presentation
• Any condition which in the Investigator's opinion makes it undesirable for the subject to participate in the trial or which would jeopardize compliance with the protocol

Other

• Any contraindication to the biopsy procedure
• Individuals deprived of liberty or placed under the authority of a tutor

• Age 18-years or older
• Patients with histological confirmation of invasive breast cancer with known receptor status suitable for neoadjuvant chemotherapy as assessed by the local investigator
• Estrogen receptor (ER)- and progesterone receptor (PR)-negative as defined by ≤1% of positive staining on immunohistochemistry
• Human epidermal growth factor receptor 2 (HER2)-negative as defined by American Society of Clinical Oncology / College of American Pathologists guidelines
• T1c-4 tumours (including inflammatory cancers), with any nodal status non candidate for conservative surgery upfront. Bilateral or multifocal cancer is permitted provided that all sites are HER2-negative and at least one site is ER- and PR-negative.
• Provision of signed and dated, written informed consent prior to any study specific procedures, sampling and analyses
• Patient with social insurance coverage